AK104 + paclitaxel + carboplatin + cisplatin + bevacizumab + Placebo
Phase 3Active 0 watching 0 views this weekπ Rising
76
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer
Trial Timeline
Aug 27, 2021 β Dec 30, 2025
NCT ID
NCT04982237About AK104 + paclitaxel + carboplatin + cisplatin + bevacizumab + Placebo
AK104 + paclitaxel + carboplatin + cisplatin + bevacizumab + Placebo is a phase 3 stage product being developed by Akeso for Cervical Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04982237. Target conditions include Cervical Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04982237 | Phase 3 | Active |
Competing Products
20 competing products in Cervical Cancer